| New drugmaker Morphic gets $52M to build on research by Harvard's Tim Springer The company is the result of decades of research by Harvard immunologist Tim Springer to perfect drugs that target common proteins called integrins.  Boston’s skyline is largely foreign-owned — and Brexit could spur even more investment The Boston skyline market has seen some $3.1 billion in investment sales volume since 2015. Care.com nabs major investment from Google Capital Online caregiver services firm Care.com has landed a $46.35 million investment from Google Capital, making it the largest shareholder in the Waltham-based company. Five things you need to know today, and a cereal-only cafe Good morning, Boston. Happy Thursday. Trump's gone, and the downtown streets are empty of angry protestors — and back to being clogged by angry drivers and pedestrians. Grab a bowl of cereal and read the five important things you need to know to help start your busy business day. Read Morning Edition >>
 Ride-for-hire bill passes Senate, adds background checks MGH says patients impacted by third-party data breach Charles River CEO: 'Companies that don’t grow, die' Merck, Moderna to develop personalized cancer vaccines in $200M deal Bay State's 3rd biggest bank, Santander fails stress test for third straight year Waltham biotech Tesaro gains $1.8B in value after ovarian cancer drug trial win Layoffs hit Braintree media company behind Magic 106.7, other radio stations GE unit is no longer 'too big to fail,' government says Cambridge diagnostic firm to double size of 'Moonshot' cancer database Read Morning Edition >> | 
